Immune checkpoint inhibitors (ICIs) have revolutionised oncology care, by enhancing the body’s T cell lymphocyte response against tumour cells. ICIs block the inhibitory signalling between tumour cells and the immune system, but consequently reduce immunological tolerance. Subsequently for some, this leads to immune-related adverse events (irAE), a spectrum term for autoimmune-like toxicities induced by ICIs that affects various tissues and organs. This limited narrative review will give a brief overview of immune checkpoint inhibitors and immune-related adverse events for laboratory professionals and review the current evidence for predictive biomarkers.
Methods
A limited narrative review was conducted by accessing Pubmed and Google from June 2023 to January 2024 to identify references published from database inception to January 2024. Language was restricted to English.
Results/findings
Professional guidance does not recommend any biomarkers for irAE prediction. Some studies have found an association between the prediction of irAE and interleukin six (IL-6), C-reactive protein (CRP), thyroid stimulating hormone (TSH), albumin, ferritin, full blood count metrics, and lactate dehydrogenase (LDH). However, these have often been single-centre retrospective studies. While an abundance of societal guidance has been produced, it is unclear what blood tests should be included within a baseline profile.
Conclusions
Presently, there is no singular biomarker routinely available in clinical laboratories that can predict the onset of irAE. A custom battery of tests may be more predictive, but evidence is currently lacking. In the meantime, due to the clinical significance of these complications, laboratory professionals should proactively support prospective studies.
RobertC. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun2020; 11(1): 3801.
2.
GuinanTJGarbuttNOlsson-BrownA. The impact of an immuno-oncology service at a regional cancer centre based in the north west of the UK. Br J Nurs2022; 31(8): 414–420.
3.
JenningsSAnsteySBowerJ, et al.Experiences of cancer immunotherapy with immune checkpoint inhibitors (ExCIm)—insights of people affected by cancer and healthcare professionals: a qualitative study protocol. BMJ Open2021; 11(5): e043750.
4.
EllengerKFlatleyMSpencerK, et al.P2.04-21 real world experience of immune checkpoint inhibitors in NSCLC: our first 10 months experience at leeds cancer centre, UK. J Thorac Oncol2018; 13(10): S738.
5.
KhairDOBaxHJMeleS, et al.Combining immune checkpoint inhibitors: established and emerging targets and strategies to improve outcomes in melanoma. Front Immunol2019; 10: 453.
6.
MichotJMBigenwaldCChampiatS, et al.Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer2016; 54: 139–148.
7.
SmithyJWFaleckDMPostowMA. Facts and hopes in prediction, diagnosis, and treatment of immune-related adverse events. Clin Cancer Res2022; 28(7): 1250–1257.
8.
BrahmerJRAbu-SbeihHAsciertoPA, et al.Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer2021; 9(6): e002435.
9.
PulendranBDavisMM. The science and medicine of human immunology. Science2020; 369(6511): eaay4014.
10.
LajqiTKöstlin-GilleNBauerR, et al.Training vs. Tolerance: the Yin/Yang of the innate immune system. Biomedicines2023; 11(3): 766.
11.
LawAMKLimEOrmandyCJ, et al.The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy. Endocr Relat Cancer2017; 24(4): R123–R144.
12.
DemariaOCornenSDaëronM, et al.Harnessing innate immunity in cancer therapy. Nature2019; 574(7776): 45–56.
13.
WooSRCorralesLGajewskiTF. Innate immune recognition of cancer. Annu Rev Immunol2015; 33: 445–474.
14.
CorralesLMatsonVFloodB, et al.Innate immune signaling and regulation in cancer immunotherapy. Cell Res2017; 27(1): 96–108.
15.
VeselyMDKershawMHSchreiberRD, et al.Natural innate and adaptive immunity to cancer. Annu Rev Immunol2011; 29: 235–271.
16.
AldertonGKBordonY. Tumour immunotherapy--leukocytes take up the fight. Nat Rev Immunol2012; 12(4): 237.
17.
KhonatFCZ. How equal is access to senior management and leadership roles in the NHS?Br J Healthc Manag2021.
18.
SwannJBSmythMJ. Immune surveillance of tumors. J Clin Invest2007; 117(5): 1137–1146.
19.
RibattiD. The concept of immune surveillance against tumors: the first theories. Oncotarget2016; 8(4): 7175–7180.
20.
AbbottMUstoyevY. Cancer and the immune system: the history and background of immunotherapy. Semin Oncol Nurs2019; 35(5): 150923.
21.
YaoYDaiW. Genomic instability and cancer. J Carcinog Mutagen2014; 5: 1000165.
22.
HanahanDWeinbergRA. Hallmarks of cancer: the next generation. Cell2011; 144(5): 646–674.
23.
ShenSVagnerSRobertC. Persistent cancer cells: the deadly survivors. Cell2020; 183(4): 860–874.
24.
LinDShenLLuoM, et al.Circulating tumor cells: biology and clinical significance. Sig Transduct Target Ther2021; 6(1): 404–424.
25.
EgenJGOuyangWWuLC. Human anti-tumor immunity: insights from immunotherapy clinical trials. Immunity2020; 52(1): 36–54.
26.
TauGRothmanP. Biologic functions of the IFN‐γ receptors. Allergy1999; 54(12): 1233–1251.
27.
O’DonnellJSTengMWLSmythMJ. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol2019; 16(3): 151–167.
28.
CappelliLCThomasMABinghamCO, et al.Immune checkpoint inhibitor–induced inflammatory arthritis as a model of autoimmune arthritis. Immunol Rev2020; 294(1): 106–123.
29.
RotteA. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res2019; 38(1): 255.
30.
PaluskieviczCMCaoXAbdiR, et al.T regulatory cells and priming the suppressive tumor microenvironment. Front Immunol2019; 10: 2453.
31.
WuZLiSZhuX. The mechanism of stimulating and mobilizing the immune system enhancing the anti-tumor immunity. Front Immunol2021; 12: 682435.
32.
Kimiz-GebologluIGulce-IzSBiray-AvciC. Monoclonal antibodies in cancer immunotherapy. Mol Biol Rep2018; 45(6): 2935–2940.
33.
PropperDJBalkwillFR. Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol2022; 19(4): 237–253.
34.
GuoZZhangRYangAG, et al. Diversity of immune checkpoints in cancer immunotherapy. Front Immunol2023; 14.
35.
AyoubNAl-ShamiKYaghanR. Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches. Breast Cancer2019; 11: 53–69.
36.
ShiravandYKhodadadiFKashaniSMA, et al.Immune checkpoint inhibitors in cancer therapy. Curr Oncol2022; 29(5): 3044–3060.
37.
JiangMHuYLinG, et al.Dosing regimens of immune checkpoint inhibitors: attempts at lower dose, less frequency, shorter course. Front Oncol2022; 12: 906251.
38.
BuchbinderEIDesaiA. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol2016; 39(1): 98–106.
39.
FranciscoLMSalinasVHBrownKE, et al.PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med2009; 206(13): 3015–3029.
40.
KeirMEButteMJFreemanGJ, et al.PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol2008; 26: 677–704.
41.
AiLChenJYanH, et al.Research status and outlook of PD-1/PD-L1 inhibitors for cancer therapy. Drug Des Devel Ther2020; 14: 3625–3649.
42.
BaxevanisCN. Immune checkpoint inhibitors in cancer therapy—how can we improve clinical benefits?Cancers2023; 15(3): 881.
43.
NICE. Surveillance decision | Evidence | Early and locally advanced breast cancer: diagnosis and management | Guidance | NICE. NICE National Institute for Health and Care Excellence. NICE; 2023.
44.
BudimirNThomasGDDolinaJS, et al.Reversing T-cell exhaustion in cancer: lessons learned from PD-1/PD-L1 immune checkpoint blockade. Cancer Immunol Res2022; 10(2): 146–153.
45.
SchneiderBJNaidooJSantomassoBD, et al.Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol2021.
46.
BermudezMVPapaS. Setting the scene – a future ‘epidemic’ of immune-related adverse events in association with checkpoint inhibitor therapy. Rheumatology2019; 58(Supplement_7): vii1–vii6.
47.
NHS Digital. Cancer registration statistics, England 2020. Leeds: NHS Digital, 2022.
48.
GhisoniEWickyABouchaabH, et al.Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: an overlooked aspect in immunotherapy. Eur J Cancer2021; 149: 153–164.
49.
ÖzdemirBCEspinosa da SilvaCArangalageD, et al.Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune-related adverse events among cancer patients. Cancer Immunol Immunother2023; 72(7): 1991–2001.
50.
NICE. Overview | Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer | Guidance | NICE. London: National Institute for Health and Care Excellence, 2022.
51.
von ItzsteinMSKhanSGerberDE. Investigational biomarkers for checkpoint inhibitor immune-related adverse event prediction and diagnosis. Clin Chem2020; 66(6): 779–793.
52.
PotoRTroianiTCriscuoloG, et al.Holistic approach to immune checkpoint inhibitor-related adverse events. Front Immunol2022; 13: 804597.
53.
ReidPDCifuASBassAR. Management of immunotherapy-related toxicities in patients treated with immune checkpoint inhibitor therapy. JAMA2021; 325(5): 482–483.
54.
TangSQTangLLMaoYP, et al.The pattern of time to onset and resolution of immune-related adverse events caused by immune checkpoint inhibitors in cancer: a pooled analysis of 23 clinical trials and 8,436 patients. Cancer Res Treat2021; 53(2): 339–354.
55.
HaanenJObeidMSpainL, et al.Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol2022; 33(12): 1217–1238.
56.
DongHQiYKongX, et al.PD-1/PD-L1 inhibitor-associated myocarditis: epidemiology, characteristics, diagnosis, treatment, and potential mechanism. Front Pharmacol2022; 13: 835510.
57.
MuntyanuANetchiporoukEGersteinW, et al.Cutaneous immune-related adverse events (irAEs) to immune checkpoint inhibitors: a dermatology perspective on management [Formula: see text]. J Cutan Med Surg2021; 25(1): 59–76.
58.
Del RiveroJCordesLMKlubo‐GwiezdzinskaJ, et al.Endocrine‐related adverse events related to immune checkpoint inhibitors: proposed Algorithms for management. Oncol2020; 25(4): 290–300.
59.
GrouthierVLebrun‐VignesBMoeyM, et al.Immune checkpoint inhibitor‐associated primary adrenal insufficiency: WHO VigiBase report analysis. Oncol2020; 25(8): 696–701.
60.
SmithKERPritzlSLYuW, et al.The timing, trajectory, and incidence of immune-related adverse events in NSCLC treated with atezolizumab. JTO Clin Res Rep2023; 4(12): 100611.
61.
WangLLPatelGChiesa-FuxenchZC, et al.Timing of onset of adverse cutaneous reactions associated with programmed cell death protein 1 inhibitor therapy. JAMA Dermatol2018; 154(9): 1057–1061.
62.
ImotoKKohjimaMHiokiT, et al.Clinical features of liver injury induced by immune checkpoint inhibitors in Japanese patients. Can J Gastroenterol Hepatol2019; 2019: 6391712.
63.
MuirCATsangVHMMenziesAM, et al.Immune related adverse events of the thyroid – a narrative review. Front Endocrinol2022; 13: 886930.
64.
MarsiglioJMcPhersonJPKovacsovics-BankowskiM, et al.A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome. Front Immunol2023; 14: 1229823.
65.
SorahJDRoseTLRadhakrishnaR, et al.Incidence and prediction of immune checkpoint inhibitor related nephrotoxicity. J Immunother2021; 44(3): 127–131.
66.
ZhongHZhouJXuD, et al.Rheumatic immune‐related adverse events induced by immune checkpoint inhibitors. Asia Pac J Clin Oncol2021; 17(3): 178–185.
67.
VerspohlSHHolderriedTBehningC, et al.Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis. Ther Adv Musculoskelet Dis2021; 13: 1759720X211006963.
68.
KaliszKRRamaiyaNHLaukampKR, et al.Immune checkpoint inhibitor therapy–related pneumonitis: patterns and management. Radiographics2019; 39(7): 1923–1937.
69.
National Cancer Institute. Common Terminology criteria for adverse events (CTCAE), version 5.0. Washington, DC: U.S. Department of Health and Human Services, 2017.
70.
ConroyMNaidooJ. Immune-related adverse events and the balancing act of immunotherapy. Nat Commun2022; 13(1): 392.
71.
HusebyeESCastinettiFCrisenoS, et al.Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. Eur J Endocrinol2022; 187(6): G1–21.
72.
ThompsonJASchneiderBJBrahmerJ, et al.Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw2022; 20(4): 387–405.
73.
Olsson-BrownA. Immune-related adverse event: myocarditis, version 1.2. Birkenhead: The Clatterbridge Cancer Centre NHS Foundation Trust, 2023.
74.
LangTCroalB. National minimum retesting intervals in pathology. A final report detailing consensus recommendations for minimum retesting intervals for use in. Pathology2015.
75.
MatsunagaTSaitoHKurodaH, et al.CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab. BMC Cancer2022; 22: 418.
76.
LuongoCMorraRGambaleC, et al.Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy. J Endocrinol Invest2021; 44(9): 1927–1933.
77.
FujisawaYYoshinoKOtsukaA, et al.Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab. J Dermatol Sci2017; 88(2): 225–231.
78.
OnoderaRChibaSNiheiS, et al.High level of C-reactive protein as a predictive factor for immune-related adverse events of immune checkpoint inhibitors in non-small cell lung cancer: a retrospective study. J Thorac Dis2023; 15(8): 4237–4247.
79.
IsonoTKagiyamaNTakanoK, et al.Outcome and risk factor of immune‐related adverse events and pneumonitis in patients with advanced or postoperative recurrent non‐small cell lung cancer treated with immune checkpoint inhibitors. Thorac Cancer2021; 12(2): 153–164.
80.
HusainBKirchbergerMErdmannM, et al.Inflammatory markers in autoimmunity induced by checkpoint inhibitors. J Cancer Res Clin Oncol2021; 147: 1623–1630.
81.
ValpioneSPasqualiSCampanaLG, et al.Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade. J Transl Med2018; 16(1): 94.
82.
EgamiSKawazoeHHashimotoH, et al.Absolute lymphocyte count predicts immune-related adverse events in patients with non-small-cell lung cancer treated with nivolumab monotherapy: a multicenter retrospective study. Front Oncol2021; 11: 618570.
83.
NakamuraYTanakaRMaruyamaH, et al.Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies. Jpn J Clin Oncol2019; 49(5): 431–437.
84.
MichailidouDKhakiARMorelliMP, et al.Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors. Sci Rep2021; 11(1): 9029.
85.
ZhangWMengYYangL, et al.Ferritin as a diagnostic, differential diagnostic, and prognostic marker for immune-related adverse events. Cancer Biol Med2021; 18(4): 1109–1117.
86.
ZhaoLLiYJiangN, et al.Association of blood biochemical indexes and antibiotic exposure with severe immune-related adverse events in patients with advanced cancers receiving PD-1 inhibitors. J Immunother2022; 45(4): 210–216.
87.
AbolhassaniARSchulerGKirchbergerMC, et al.C-reactive protein as an early marker of immune-related adverse events. J Cancer Res Clin Oncol2019; 145(10): 2625–2631.
88.
BaiRChenNChenX, et al.Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events. Cancer Biol Med2021; 18(4): 1118–1133.
89.
VerheijdenRJMayAMBlankCU, et al.Lower risk of severe checkpoint inhibitor toxicity in more advanced disease. ESMO Open2020; 5(6): e000945.
90.
FanXWangDZhangW, et al.Inflammatory markers predict survival in patients with advanced gastric and colorectal cancers receiving anti–PD-1 therapy. Front Cell Dev Biol2021; 9: 638312.
91.
PavanACalvettiLDal MasoA, et al.Peripheral blood markers identify risk of immune‐related toxicity in advanced non‐small cell lung cancer treated with immune‐checkpoint inhibitors. Oncol2019; 24(8): 1128–1136.
92.
RebuzziSEPrelajAFriedlaenderA, et al.Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors. Crit Rev Oncol Hematol2022; 179: 103806.
93.
DabanAGonninCPhanL, et al.Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs). OncoImmunology2023; 12(1): 2204754.
94.
LeeCSDevoeCEZhuX, et al.Pretreatment nutritional status and response to checkpoint inhibitors in lung cancer. Lung Cancer Manag2020; 9(2): LMT31.
95.
MathiasKRouhaniSOlsonD, et al.Association between rheumatic autoantibodies and immune-related adverse events. Oncol2023; 28(5): 440–448.
96.
LiuJLiSZhangS, et al.Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab. J Clin Lab Anal2019; 33(8): e22964.
97.
SuhKJKimSHKimYJ, et al.Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody. Cancer Immunol Immunother2018; 67(3): 459–470.
98.
MuirCAWoodCCGClifton-BlighRJ, et al.Association of antithyroid antibodies in checkpoint inhibitor-associated thyroid immune-related adverse events. J Clin Endocrinol Metab2022; 107(5): e1843–e1849.
99.
IzawaNShiokawaHOnukiR, et al.The clinical utility of comprehensive measurement of autoimmune disease-related antibodies in patients with advanced solid tumors receiving immune checkpoint inhibitors: a retrospective study. ESMO Open2022; 7(2): 100415.
100.
OkadaNIwamaSOkujiT, et al.Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study. Br J Cancer2020; 122(6): 771–777.
101.
SakakidaTIshikawaTUchinoJ, et al.Clinical features of immune-related thyroid dysfunction and its association with outcomes in patients with advanced malignancies treated by PD-1 blockade. Oncol Lett2019; 18(2): 2140–2147.
102.
PollackRMKaganMLotemM, et al.Baseline TSH level is associated with risk of anti–PD-1–induced thyroid dysfunction. Endocr Pract2019; 25(8): 824–829.
103.
BrilliLDanielliRCampanileM, et al.Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy. J Endocrinol Invest2021; 44(8): 1719–1726.
104.
LordeNElgharablyAKalariaT. Impact of variation between assays and reference intervals in the diagnosis of endocrine disorders. Diagnostics2023; 13(22): 3453.
105.
YuYWangSSuN, et al.Increased circulating levels of CRP and IL-6 and decreased frequencies of T and B lymphocyte subsets are associated with immune-related adverse events during combination therapy with PD-1 inhibitors for liver cancer. Front Oncol2022; 12.
106.
WangDYSalemJECohenJV, et al.Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol2018; 4(12): 1721–1728.
107.
HuBYangXRXuY, et al.Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res2014; 20(23): 6212–6222.
108.
BannaGLFriedlaenderATagliamentoM, et al.Biological rationale for peripheral blood cell-derived inflammatory indices and related prognostic scores in patients with advanced non-small-cell lung cancer. Curr Oncol Rep2022; 24(12): 1851–1862.
109.
AnpalakhanSSignoriACortelliniA, et al.Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: an INVIDIa-2 study sub-analysis. iScience2023; 26(11): 107970.
110.
ZhangZXieTQiC, et al.Peripheral blood biomarkers predictive of efficacy outcome and immune-related adverse events in advanced gastrointestinal cancers treated with checkpoint inhibitors. Cancers2022; 14(15): 3736.
111.
ZhangWTanYLiY, et al.Neutrophil to Lymphocyte ratio as a predictor for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Immunol2023; 14: 1234142.
